Background
Methods
Patients
Diagnostic and staging scheme for lung cancer and IPF
Radiation treatment
Follow-up
Statistical analysis
Results
Patient and tumor characteristics
Characteristics | X-ray (n = 22) | Proton (n = 8) | p value |
---|---|---|---|
Age [years; median (range)] | 75 (55–84) | 77 (62–85) | 0.640 |
Sex | |||
Female | 0 (0%) | 1 (12.5%) | 0.092 |
Male | 22 (100%) | 7 (87.5%) | |
Smoking Status | |||
Never smoker | 0 (0%) | 1 (12.5%) | 0.092 |
Current or Ex-smoker | 22 (100%) | 7 (87.5%) | |
ECOG performance | |||
0–1 | 13 (59.1%) | 8 (100%) | 0.031 |
2–3 | 9 (40.9%) | 0 (0%) | |
Clinical Stage | |||
IA-IB | 15 (68.2%) | 4 (50.0%) | 0.361 |
IIA-IIB | 7 (31.8%) | 4 (50.0%) | |
Histology | |||
Adenocarcinoma | 5 (31.3%) | 2 (28.6%) | 0.775 |
Squamous cell carcinoma | 10 (62.5%) | 5 (71.4%) | |
Others | 1 (6.2%) | 0 (0%) | |
Not proven | 6 | 1 | |
Pulmonary function test | |||
FEV1 | |||
> 50% | 21 (95.5%) | 8 (100%) | 0.540 |
≤ 50% | 1 (4.5%) | 0 (0%) | |
DLCO | |||
> 60% | 9 (40.9%) | 2 (25.0%) | 0.424 |
≤ 60% | 13 (59.1%) | 6 (75.0%) | |
DLCO | |||
> 40% | 20 (90.9%) | 7 (87.5%) | 0.783 |
≤ 40% | 2 (9.1%) | 1 (12.5%) | |
GAP index | |||
1 | 9 (40.9%) | 1 (12.5%) | 0.144 |
2–3 | 13 (59.1%) | 7 (87.5%) |
Characteristics | X-ray (n = 22) | Proton (n = 8) | p value |
---|---|---|---|
Clinical target volume (cm3) | 73.3 ± 52.6 | 206.1 ± 100.6 | 0.007 |
Total lung | |||
Mean dose (cGy or CcGE) | 809.8 ± 368.1 | 796.9 ± 475.2 | 0.938 |
V5 (%) | 28.4 ± 9.7 | 23.1 ± 11.6 | 0.216 |
V10 (%) | 19.8 ± 8.8 | 18.7 ± 10.5 | 0.782 |
V20 (%) | 13.1 ± 8.1 | 14.3 ± 8.6 | 0.717 |
Heart | |||
V45 (%) | 0.2 ± 0.5 | 0.1 ± 0.2 | 0.855 |
Esophagus | |||
Maximum dose (cGy or CcGE) | 1588.5 ± 1030.2 | 1261.4 ± 1216.3 | 0.469 |
Mean dose (cGy or CcGE) | 408.0 ± 301.4 | 257.9 ± 304.6 | 0.239 |
Spinal cord | |||
Maximum dose (cGy or CcGE) | 1141.4 ± 761.5 | 1487.0 ± 1491.0 | 0.548 |
Survival outcomes and treatment-related complications
Characteristics | X-ray (n = 22) | Proton (n = 8) | p value |
---|---|---|---|
All patients
| |||
Treatment-related death | 4/22 (18.2%) | 0/8 (0%) | 0.140 |
6 months OS | 67.9% | 100% | 0.081 |
1 year OS | 46.4% | 66.7% | |
GAP stage I
| n = 9 | n = 1 | |
6 months OS | 88.9% | 100% | 0.501 |
1 year OS | 76.2% | 100% | |
GAP stage II-III
| n = 13 | n = 7 | 0.036 |
6 months OS | 52.7% | 100% | |
1 year OS | 26.4% | 50.0% |
No. | Age/Sex | PS | Smoking | FEV1 / DLCO | Underlying disease | Stage | RT technique | Time to TRC (months) | Survival (months) |
---|---|---|---|---|---|---|---|---|---|
1 | 77/M | 1 | Ex-, 30PY | 2.2 L, 84% / 58% | IPF and COPD | T2a N0 | 3DCRT 60 Gy/15 Fx’s | 3 | 4 |
2 | 79/M | 2 | Ex-, 40PY | 2.3 L, 85% / 77% | IPF | T1b N1 | 3DCRT 60 Gy/15 Fx’s | 2 | 3 |
3 | 78/M | 2 | Ex-, 100PY | 2.5 L, 131% / 60% | IPF and COPD | T2a N0 | SBRT, 60 Gy/4 Fx’s | 2 | 8 |
4 | 69/M | 1 | Ex-, 120PY | 2.0 L, 78% / 31% | IPF | T2a N0 | SBRT 60 Gy/4 Fx’s | 4 | 5 |
Discussion
Number of Patients | Median follow-up (month, range) | Treatment | Median total dose | Grade ≥ 4 RP | |
---|---|---|---|---|---|
Yamashita et al. | 13 | 14.7 (0.3–76.2) | SBRT | 48.0 Gy | 7 (53.8%) |
Lee et al. | 14 | 15.5 (6.1–40.9) | 3DCRT | 56.9 Gy | 5 (35.7%) |
Yamaguchi et al. | 16 | – | SBRT | 48.0 Gy | 2 (12.5%) |
Ono et al. | 16 | 12.0 (4–39) | PBT | 80.0 Gy (RBE) | 1 (6.3%) |
Current study | 30 | 11.0 (2–51) | X-raya/PBT | 60.0 Gy | 18.2% (4/22) in X-ray 0% (0/8) in PBT |